Note: Funding Information: The REMAP-CAP trial is funded by the Platform for European Preparedness Against Re-emerging Epidemics consortium by the European Union , FP7-HEALTH-2013-INNOVATION-1 (grant 602525 ), the Australian National Health and Medical Research Council (grant APP1101719 ), the New Zealand Health Research Council (grant 16/631 ), the Canadian Institute of Health Research Strategy for Patient-Oriented Research Innovative Clinical Trials Programme (grant 158584 ), the UK National Institute for Health Research ( NIHR ) and the NIHR Imperial Biomedical Research Centre , the Health Research Board of Ireland (grant CTN 2014-012), the UPMC Learning While Doing Programme, the Breast Cancer Research Foundation , the French Ministry of Health (grant PHRC-20-0147), and the Minderoo Foundation; EU Patient-centric Clinical Trial Platforms has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 853966-2. This joint undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA , Children's Tumor Foundation, Global Alliance for TB Drug Development non-profit organization, and Springworks Therapeutics Inc. This publication reflects only the authors' views. The joint undertaking is not responsible for any use that may be made of the information it contains.